Alexandre Mamedov

4.9k total citations · 2 hit papers
85 papers, 3.3k citations indexed

About

Alexandre Mamedov is a scholar working on Pulmonary and Respiratory Medicine, Radiation and Hematology. According to data from OpenAlex, Alexandre Mamedov has authored 85 papers receiving a total of 3.3k indexed citations (citations by other indexed papers that have themselves been cited), including 65 papers in Pulmonary and Respiratory Medicine, 39 papers in Radiation and 8 papers in Hematology. Recurrent topics in Alexandre Mamedov's work include Prostate Cancer Treatment and Research (61 papers), Prostate Cancer Diagnosis and Treatment (60 papers) and Advanced Radiotherapy Techniques (39 papers). Alexandre Mamedov is often cited by papers focused on Prostate Cancer Treatment and Research (61 papers), Prostate Cancer Diagnosis and Treatment (60 papers) and Advanced Radiotherapy Techniques (39 papers). Alexandre Mamedov collaborates with scholars based in Canada, United States and Australia. Alexandre Mamedov's co-authors include Liying Zhang, Andrew Loblaw, Laurence Klotz, Robert K. Nam, Adam Lam, Danny Vesprini, Suneil Jain, Vibhuti Jethava, Perakaa Sethukavalan and Toshihiro Yamamoto and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Annals of Internal Medicine.

In The Last Decade

Alexandre Mamedov

83 papers receiving 3.2k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Long-Term Follow-Up of a Large Active Surveillance Cohort of Patients With Prostate Cancer

2014 824 citations Laurence Klotz, Danny Vesprini et al. profile →
Clinical Results of Long-Term Follow-Up of a Large, Active Surveillance Cohort With Localized Prostate Cancer

2009 796 citations Laurence Klotz, Liying Zhang et al. profile →

Peers

Alexandre Mamedov

PRM

RADIA

SURGE

ONCOL

RHEUM

Ignace Billiet Belgium

Daniel Hunt United States

Alwyn M. Reuther United States

Jean‐Léon Lagrange France

T. Kälble Germany

Carlos Vargas United States

Valérie Fonteyne Belgium

Sarat Chander Australia

Stéphanie Peeters Netherlands

Élisabeth Luporsi France

Ignace Billiet Belgium

Alexandre Mamedov

1.7k ×0.6

PRM

376 ×0.4

RADIA

443 ×0.7

SURGE

283 ×0.6

ONCOL

185 ×0.5

RHEUM

Citations per year, relative to Alexandre Mamedov Alexandre Mamedov (= 1×) peers Ignace Billiet

Countries citing papers authored by Alexandre Mamedov

Since Specialization

Citations

This map shows the geographic impact of Alexandre Mamedov's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Alexandre Mamedov with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Alexandre Mamedov more than expected).

Fields of papers citing papers by Alexandre Mamedov

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Alexandre Mamedov. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Alexandre Mamedov. The network helps show where Alexandre Mamedov may publish in the future.

Co-authorship network of co-authors of Alexandre Mamedov

This figure shows the co-authorship network connecting the top 25 collaborators of Alexandre Mamedov. A scholar is included among the top collaborators of Alexandre Mamedov based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Alexandre Mamedov. Alexandre Mamedov is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Klotz, Laurence, et al.. (2025). Prognostic value of MR visibility/invisibility in men on Active Surveillance. Prostate Cancer and Prostatic Diseases. 28(4). 879–886. 2 indexed citations

Ong, Wee Loon, Harvey Quon, Patrick Cheung, et al.. (2024). Stereotactic Radiation Therapy for Localized Prostate Cancer: 10-Year Outcomes From Three Prospective Trials. International Journal of Radiation Oncology*Biology*Physics. 121(2). 325–330. 2 indexed citations

Mozessohn, Lee, Ning Liu, Brian Leber, et al.. (2023). Impact of Frailty on Health Care Resource Utilization and Costs of Care in Myelodysplastic Syndromes. JCO Oncology Practice. 19(4). e559–e569. 3 indexed citations

Song, Jiheon, Mark T. Corkum, Andrew Loblaw, et al.. (2023). 44 Dosimetric Parameters Predictive of Treatment-Related Toxicity in High Dose-Rate Brachytherapy as Monotherapy for Prostate Cancer. Radiotherapy and Oncology. 186. S22–S23.

Song, Jiheon, Mark T. Corkum, D.A. Loblaw, et al.. (2023). Dosimetric Parameters Predictive of Treatment-Related Toxicity in High Dose-Rate Brachytherapy as Monotherapy for Prostate Cancer. International Journal of Radiation Oncology*Biology*Physics. 117(2). e438–e439. 1 indexed citations

Ong, Wee Loon, Patrick Cheung, Hans T. Chung, et al.. (2023). To Boost or Not to Boost: Pooled Analyses From 2-Fraction SABR Trials for Localized Prostate Cancer. International Journal of Radiation Oncology*Biology*Physics. 117(5). 1153–1162. 6 indexed citations

Correa, Rohann, Gerard Morton, Hans T. Chung, et al.. (2022). Two-fraction stereotactic ablative radiotherapy (SABR) versus two-fraction high dose rate (HDR) brachytherapy for localized prostate cancer: Does dose heterogeneity matter?. Radiotherapy and Oncology. 169. 51–56. 7 indexed citations

Glicksman, Rachel, Andrew Loblaw, Gerard Morton, et al.. (2021). Elective pelvic nodal irradiation with a simultaneous hypofractionated integrated prostate boost for localized high risk prostate cancer: Long term results from a prospective clinical trial. Radiotherapy and Oncology. 163. 21–31. 12 indexed citations

Alayed, Yasir, Andrew Loblaw, Merrylee McGuffin, et al.. (2020). Single-fraction HDR brachytherapy as monotherapy in low and intermediate risk prostate cancer: Outcomes from two clinical trials with and without an MRI-guided boost. Radiotherapy and Oncology. 154. 29–35. 18 indexed citations

10.

Roy, Soumyajit, Andrew Loblaw, Patrick Cheung, et al.. (2019). Prostate-specific Antigen Bounce After Stereotactic Body Radiotherapy for Prostate Cancer: A Pooled Analysis of Four Prospective Trials. Clinical Oncology. 31(9). 621–629. 4 indexed citations

11.

Alayed, Yasir, Patrick Cheung, Geordi Pang, et al.. (2018). Dose escalation for prostate stereotactic ablative radiotherapy (SABR): Late outcomes from two prospective clinical trials. Radiotherapy and Oncology. 127(2). 213–218. 41 indexed citations

12.

Vijenthira, Abi, Jeannie Callum, Yulia Lin, et al.. (2018). The management and outcomes of patients with myelodysplastic syndrome with persistent severe thrombocytopenia: An observational single centre registry study. Leukemia Research. 76. 76–81. 11 indexed citations

13.

Vijenthira, Abi, Richard A. Wells, Jeannie Callum, et al.. (2017). Rates of Severe Bleeding Are Low in Patients with MDS and Severe Thrombocytopenia and May be Mitigated By Tranexamic Acid. Blood. 130. 1691. 1 indexed citations

14.

Helou, Joelle, Laura D’Alimonte, Harvey Quon, et al.. (2017). Stereotactic ablative radiotherapy in the treatment of low and intermediate risk prostate cancer: Is there an optimal dose?. Radiotherapy and Oncology. 123(3). 478–482. 25 indexed citations

15.

Musunuru, Hima Bindu, Harvey Quon, Melanie Davidson, et al.. (2016). Dose-escalation of five-fraction SABR in prostate cancer: Toxicity comparison of two prospective trials. Radiotherapy and Oncology. 118(1). 112–117. 55 indexed citations

16.

Quon, Harvey, Hima Bindu Musunuru, Patrick Cheung, et al.. (2016). Dose-Escalated Stereotactic Body Radiation Therapy for Prostate Cancer: Quality-of-Life Comparison of Two Prospective Trials. Frontiers in Oncology. 6. 185–185. 17 indexed citations

17.

Gladwish, Adam, Andrew Loblaw, Patrick Cheung, et al.. (2015). Accelerated Hypofractioned Postoperative Radiotherapy for Prostate Cancer: A Prospective Phase I/II Study. Clinical Oncology. 27(3). 145–152. 13 indexed citations

18.

Helou, Joelle, Gerard Morton, Liying Zhang, et al.. (2014). A comparative study of quality of life in patients with localized prostate cancer treated at a single institution: Stereotactic ablative radiotherapy or external beam+high dose rate brachytherapy boost. Radiotherapy and Oncology. 113(3). 404–409. 14 indexed citations

19.

Mamedov, Alexandre, et al.. (2011). Vitamin D insufficiency is common in patients with nonmetastatic prostate cancer. Nutrition Research. 31(1). 21–26. 18 indexed citations

20.

Morton, Gerard, D.A. Loblaw, Hans T. Chung, et al.. (2010). Health-Related Quality of Life After Single-Fraction High-Dose-Rate Brachytherapy and Hypofractionated External Beam Radiotherapy for Prostate Cancer. International Journal of Radiation Oncology*Biology*Physics. 80(5). 1299–1305. 57 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact